In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) continues to be a malignancy with an unmet clinical demand. Development of radioimmunoconjugates which target cancer-specific receptors provides an opportunity for radioimmunotherapy of both metastatic and primary PDAC. In this study, we ch...

Full description

Bibliographic Details
Published in:EJNMMI Radiopharmacy and Chemistry
Main Authors: Ashleigh Hull, William Hsieh, William Tieu, Dylan Bartholomeusz, Yanrui Li, Eva Bezak
Format: Article
Language:English
Published: SpringerOpen 2023-08-01
Subjects:
Lutetium-177
Radioimmunotherapy
Pancreatic cancer
MUC1
C595
Online Access:https://doi.org/10.1186/s41181-023-00204-4

Internet

https://doi.org/10.1186/s41181-023-00204-4

Similar Items